Beta-1A
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2269 publications
Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.
Journal: Journal of clinical medicine
Published: February 01, 2026
The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.
Journal: Multiple sclerosis and related disorders
Published: December 20, 2025
Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system.
Journal: Multiple sclerosis and related disorders
Published: December 12, 2025
Therapeutic Outcomes of Fingolimod and Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: A Real-World Study from Jordan.
Journal: Medicina (Kaunas, Lithuania)
Published: December 11, 2025
Reduced peripheral serotonin levels in women with multiple sclerosis: associations with underweight status, treatment duration, and use of interferon beta 1a.
Journal: Frontiers in cellular neuroscience
Published: November 24, 2025
Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial.
Journal: Journal of neuroimmunology
Published: November 08, 2025
Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy.
Journal: Journal of autoimmunity
Published: November 07, 2025
Evaluating use of disease-modifying therapies for multiple sclerosis using claims data.
Journal: Frontiers in health services
Published: September 29, 2025
Drug-induced osteoporosis/osteopenia: a pharmacovigilance analysis using the FDA Adverse Event Reporting System database.
Journal: Clinical and experimental rheumatology
Published: September 22, 2025
The efficacy of disease-modifying therapies in patients with clinically isolated syndrome: a systematic review and network meta-analysis.
Journal: Scientific reports
Published: September 17, 2025
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.
Journal: Journal of child neurology
Published: September 16, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Last Updated: 04/28/2026